|
BCN6049 |
Quercetin
|
|
Quercetin is one of the most prominent dietary antioxidants, it is claimed to exert beneficial health effects, this includes protection against various diseases such as osteoporosis, certain forms of cancer, pulmonary and cardiovascular diseases but also against aging. It is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4±0.6 μM, 3.0±0.0 μM and 5.4±0.3 μM for PI3K γ, PI3K δ and PI3K β, respectively. It also attenuated the function VEGFR, androgen receptor and the expressions of NF-κB, IL Receptor, FAK, ERK,Nrf2. |
|
BCN6059 |
Syringin
|
|
Syringin (Eleutheroside B) has neuroprotective, tonic, adaptogenic, antitumour, anti- platelet aggregation, anti-inflammatory, antinociceptive ,and immune-modulating properties. It reduced the expression levels of inducible NO synthase (iNOS) ,COX,TNF-α, Beta Amyloid, and Caspase. |
|
BCN6197 |
Pomolic acid
|
|
Pomolic acid has anti-cancer, anti-inflammatory and apoptotic activities, it can induce apoptosis in SK-OV-3 cells, which is mediated by the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways. Pomolic acid is a potent inhibitor of the aggregation of human platelets induced by ADP and Epinephrine, exhibits IC50 values close to 60 nM and 20 nM, respectively; pomolic acid does not inhibit human platelet aggregation induced by PAF, collagen, U46619 (thromboxane analogue), TRAP or arachidonic acid; suggests that the hypotensive and platelet anti-aggregating effects of pomolic acid and its potential role in cardiovascular therapy. |
|
BCN6305 |
Stevioside
|
|
Stevioside is a safe natural sweetener, has no allergic reactions, suited for both diabetics, and PKU patients, as well as for obese persons intending to lose weight by avoiding sugar supplements in the diet. Stevioside enjoys a dual positive effect by acting as an antihyperglycemic and a blood pressure-lowering substance, it may have therapeutic potential in the treatment of type 2 diabetes and the metabolic syndrome.Stevioside exerts anti-inflammatory and anti-apoptotic properties by inhibiting the release of cytokines and the activation of TLR2 and proteins of the NF-κB and MAPK signaling pathways, as well as caspase-3 and Bax. |
|
BCN6706 |
Yangambin
|
|
1. Yangambin is a selective antagonist of the cardiovascular effects of platelet activating factor (PAF) and therefore constitutes a potential therapeutic agent in different shock states where abnormal PAF release is supposed to play an important role.
2. Yangambin has central nervous system activity, it presents a depressant activity in the open field, forced swimming and pentobarbital sleeping time tests.
3. Yangambin has hypotensive effect, which is probably due to a peripheral vasodilatation that involves, at least, the inhibition the Ca2+ influx through voltage-gated Ca2+ channels. |
